0001762239 2025-11-01 2026-04-30 0001762239 2026-06-10 0001762239 2026-04-30 0001762239 2025-10-31 0001762239 us-gaap:SeriesAPreferredStockMember 2026-04-30 0001762239 us-gaap:SeriesAPreferredStockMember 2025-10-31 0001762239 us-gaap:SeriesBPreferredStockMember 2026-04-30 0001762239 us-gaap:SeriesBPreferredStockMember 2025-10-31 0001762239 2026-02-01 2026-04-30 0001762239 2025-02-01 2025-04-30 0001762239 2024-11-01 2025-04-30 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2025-10-31 0001762239 us-gaap:CommonStockMember 2025-10-31 0001762239 us-gaap:AdditionalPaidInCapitalMember 2025-10-31 0001762239 us-gaap:RetainedEarningsMember 2025-10-31 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2026-01-31 0001762239 us-gaap:CommonStockMember 2026-01-31 0001762239 us-gaap:AdditionalPaidInCapitalMember 2026-01-31 0001762239 us-gaap:RetainedEarningsMember 2026-01-31 0001762239 2026-01-31 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2024-10-31 0001762239 us-gaap:CommonStockMember 2024-10-31 0001762239 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001762239 us-gaap:RetainedEarningsMember 2024-10-31 0001762239 2024-10-31 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2025-01-31 0001762239 us-gaap:CommonStockMember 2025-01-31 0001762239 us-gaap:AdditionalPaidInCapitalMember 2025-01-31 0001762239 us-gaap:RetainedEarningsMember 2025-01-31 0001762239 2025-01-31 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2025-11-01 2026-01-31 0001762239 us-gaap:CommonStockMember 2025-11-01 2026-01-31 0001762239 us-gaap:AdditionalPaidInCapitalMember 2025-11-01 2026-01-31 0001762239 us-gaap:RetainedEarningsMember 2025-11-01 2026-01-31 0001762239 2025-11-01 2026-01-31 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2026-02-01 2026-04-30 0001762239 us-gaap:CommonStockMember 2026-02-01 2026-04-30 0001762239 us-gaap:AdditionalPaidInCapitalMember 2026-02-01 2026-04-30 0001762239 us-gaap:RetainedEarningsMember 2026-02-01 2026-04-30 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2024-11-01 2025-01-31 0001762239 us-gaap:CommonStockMember 2024-11-01 2025-01-31 0001762239 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-01-31 0001762239 us-gaap:RetainedEarningsMember 2024-11-01 2025-01-31 0001762239 2024-11-01 2025-01-31 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2025-02-01 2025-04-30 0001762239 us-gaap:CommonStockMember 2025-02-01 2025-04-30 0001762239 us-gaap:AdditionalPaidInCapitalMember 2025-02-01 2025-04-30 0001762239 us-gaap:RetainedEarningsMember 2025-02-01 2025-04-30 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2026-04-30 0001762239 us-gaap:CommonStockMember 2026-04-30 0001762239 us-gaap:AdditionalPaidInCapitalMember 2026-04-30 0001762239 us-gaap:RetainedEarningsMember 2026-04-30 0001762239 kavl:ConvertiblePreferredStockSeriesBMember 2025-04-30 0001762239 us-gaap:CommonStockMember 2025-04-30 0001762239 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0001762239 us-gaap:RetainedEarningsMember 2025-04-30 0001762239 2025-04-30 0001762239 2024-11-01 2025-10-31 0001762239 kavl:BidiMember 2025-11-01 2026-04-30 0001762239 kavl:BidiMember 2024-11-01 2025-04-30 0001762239 srt:MinimumMember 2025-11-01 2026-04-30 0001762239 srt:MaximumMember 2025-11-01 2026-04-30 0001762239 2025-05-30 0001762239 2026-03-17 0001762239 2026-03-02 2026-03-17 0001762239 2026-04-09 0001762239 2026-04-02 2026-04-09 0001762239 us-gaap:CommonStockMember 2025-11-01 2026-04-30 0001762239 kavl:DirectorsAndOfficersMember 2025-11-01 2026-04-30 0001762239 us-gaap:CommonStockMember 2025-02-01 2025-04-30 0001762239 us-gaap:CommonStockMember 2024-11-01 2025-04-30 0001762239 us-gaap:StockOptionMember 2026-02-01 2026-04-30 0001762239 us-gaap:StockOptionMember 2025-11-01 2026-04-30 0001762239 kavl:CommonStockWarrantsMember 2025-11-01 2026-04-30 0001762239 kavl:CommonStockWarrantsMember 2026-04-30 0001762239 us-gaap:StockOptionMember 2025-10-31 0001762239 srt:MinimumMember us-gaap:StockOptionMember 2025-10-31 0001762239 srt:MaximumMember us-gaap:StockOptionMember 2025-10-31 0001762239 us-gaap:StockOptionMember 2025-11-01 2026-04-30 0001762239 us-gaap:StockOptionMember 2026-04-30 0001762239 srt:MinimumMember us-gaap:StockOptionMember 2026-04-30 0001762239 srt:MaximumMember us-gaap:StockOptionMember 2026-04-30 0001762239 us-gaap:WarrantMember 2025-10-31 0001762239 srt:MinimumMember us-gaap:WarrantMember 2025-10-31 0001762239 srt:MaximumMember us-gaap:WarrantMember 2025-10-31 0001762239 us-gaap:WarrantMember 2025-11-01 2026-04-30 0001762239 us-gaap:WarrantMember 2026-04-30 0001762239 srt:MinimumMember us-gaap:WarrantMember 2026-04-30 0001762239 srt:MaximumMember us-gaap:WarrantMember 2026-04-30 0001762239 kavl:PMILicenseAgreementMember 2026-02-01 2026-04-30 0001762239 kavl:PMILicenseAgreementMember 2025-11-01 2026-04-30 0001762239 kavl:PMILicenseAgreementMember 2026-04-30 0001762239 kavl:PMILicenseAgreementMember 2025-02-01 2025-04-30 0001762239 kavl:PMILicenseAgreementMember 2024-11-01 2025-04-30 0001762239 kavl:PMILicenseAgreementMember 2025-04-30 iso4217:USD shares iso4217:USD shares pure false --10-31 2026 Q2 0001762239

10-Q true 2026-04-30 false 000-56016 KAIVAL BRANDS INNOVATIONS GROUP, INC. DE 83-3492907 1317 Edgewater Dr #730 Orlando FL 32804 (833) 452-4825 Yes Yes Non-accelerated Filer true false false 19535402

277951

534406

80000

120000

15806

14850

50000

423757

669256

423757

669256

339419

349289

30000 50000

75000

170000

444419

569289

444419

569289

0.001

3000000

0.001

900000

900

0.001

1000000000

19535402

11593402

19535

11593

55247349

54180589

-55288446

-54093115

-20662

99967

423757

669256

4073 46755 37530 42972 130468 202893

37530

47045

130468

249648

37530

47045

130468

249648

612074

1331183

1325799

5609716

707626 707626

612074

2038809

1325799

6317342

1798 1798

4091

8183

-5889

-9981

-574544

-1997653

-1195331

-6077675

-18942

-574544

-1997653

-1195331

-6058733

22500

-574544

-1997653

-1195331

-6081233

-0.04

-0.17

-0.08

-0.58

15625290

11542302

14347096

10506114

900000

900

11593402

11593

54180589

-54093115

99967

-2950000

-2950

2950

4892000

4892

1010551

1015443

2445

-620787

900000

900

13535402

13535

55196535

-54713902

497068

6000000

6000

18320

24320

32494

-574544

900000

900

19535402

19535

55247349

-55288446

-20662

900000

900

8517302

8517

51269485

-37463230

13815672

3025000

3025

2870725

2873750

22500

31302

-4061080

900000

900

11542302

11542

54149012

-41524310

12637144

2445

-1997653

900000

900

11542302

11542

54151457

-43521963

10641936

-1195331

-6058733

50000

24320

2873750

393552

39283 707626 1798

34939

33747

102410

-40000

-193571

956

-278820

9870

-48164

-20000

-96683

-95000

97469

-98756

-1171898

-1483982

100000

-100000

1015443

207616

405000

1015443

-612616

-256455

-2096598

534406

3902300

277951

1805702

8183

2950

22500

Note 1 – Organization and Description of Business Kaival Brands Innovations Group, Inc. (the “Company,” the “Registrant,” “we,” “us,” or “our”), formerly known as Quick Start Holdings, Inc., was incorporated on September 4, 2018, in the State of Delaware. Description of Business On March 11, 2022, the Company formed Kaival Brands International, LLC, a Delaware limited liability company (herein referred to as “KBI”), as a wholly owned subsidiary of the Company, for the purpose of entering into an international licensing agreement with Philip Morris Products S.A. (“PMPSA”), a wholly owned affiliate of Philip Morris International Inc. (“PMI”). On June 13, 2022, the Company’s wholly owned subsidiary, KBI, entered into the PMI License Agreement with PMPSA, a wholly owned affiliate of PMI, for the development and distribution of ENDS products in certain markets outside of the United States, subject to market (or regulatory) assessment. The PMI License Agreement grants to PMPSA a license of certain intellectual property rights relating to Bidi’s ENDS device, known as the BIDI® Stick in the United States, as well as potentially newly developed devices, to permit PMPSA to manufacture, promote, sell, and distribute such ENDS device and newly developed devices, in international markets, outside of the United States. Our primary source of revenue is from KBI royalties from PMI under the PMI License Agreement. Historically, the Company’s business focused on the sale, marketing and distribution of ENDS products, primarily the BIDI® Stick disposable e-cigarette product manufactured by Bidi. Under an exclusive distribution agreement with Bidi, the Company distributed BIDI® Stick products to wholesalers and retailers within the United States and generated revenue primarily from the resale of these products. Beginning in 2024, the Company significantly reduced and ultimately ceased its ENDS distribution activities due to regulatory developments affecting ENDS products in the United States, including FDA marketing denial orders and patent litigation involving Bidi products. As a result, the Company no longer generates revenue from the distribution of ENDS products and has transitioned its focus toward royalty revenue generated under its international licensing agreement with Philip Morris Products S.A. and the development and monetization of intellectual property assets.

Note 2 – Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the financial statements of the Company’s wholly-owned subsidiaries, Kaival Labs and Kaival Brands International. Intercompany transactions are eliminated. Basis of Presentation The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent audited financial statements contained within the Company’s Annual Report on Form 10-K, filed with the SEC on January 29, 2026 (the “2025 Annual Report”). In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full fiscal year. Notes to the consolidated financial statements, which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period as reported in the 2025 Annual Report, have been omitted. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates. Cash The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of April 30, 2026, and October 31, 2025. The Federal Deposit Insurance Corporation (“FDIC”) insures deposits according to the ownership category in which the funds are insured and how the accounts are titled. The standard deposit insurance coverage limit is $250,000 per depositor, per FDIC-insured bank, per ownership category. The Company had uninsured cash of $27,951 and $284,406 as of April 30, 2026, and October 31, 2025, respectively. Advertising and Promotion All advertising, promotion and marketing expenses, including commissions, are expensed when incurred. Accounts Receivable and Reserve for Credit Loss Accounts receivable pertain to contracts with customers who are granted credit by the Company in the ordinary course of business and are recorded at the invoiced amount. Accounts receivable does not bear interest. Accounts receivable presented on the consolidated balance sheet are adjusted for any write-offs and net of allowance for credit losses. The Company’s reserve for credit losses is developed by using relevant available information including historical collection and loss experience, current economic conditions, prevailing economic conditions, supportable forecasted economic conditions and evaluations of customer balances. Once a receivable is deemed uncollectible after collection efforts have been exhausted, it is written off against the reserve for credit losses. The Company closely monitors the credit quality of its customers and does not generally require collateral or other security on receivables. The reserve for credit losses is measured on a collective basis when similar risk characteristics exist. Based upon management’s assessment of the accounts receivable aging and the customers’ payment history, the Company has determined that no reserve for credit losses is required as of April 30, 2026 and October 31, 2025. Credit Risk Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of purchases of inventories, accounts payable, accounts receivable, and revenue. The Company performs periodic credit evaluations of its customers and generally does not require collateral on trade receivables. Historically, the Company has not experienced significant credit losses. Leases The Company determines if a contract contains a lease at commencement of the arrangement based on whether it has the right to obtain substantially all of the economic benefits from the use of an identified asset and whether it has the right to direct the use of an identified asset in exchange for consideration, which relates to an asset which the Company does not own. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company recognizes lease liabilities at the present value of the future lease payments and a corresponding ROU asset at the lease commencement date. The interest rate used to determine the present value of the future lease payments is the rate implicit in the lease unless that rate cannot be readily determined. When the interest rate implicit in the lease is not readily determinable, the interest rate used to determine the present value of the future lease payments is the Company’s Incremental Borrowing Rate (“IBR”). The IBR is a hypothetical rate based on the Company’s understanding of what its credit rating would be to borrow and resulting interest the Company would pay to borrow an amount equal to the lease payments in a similar economic environment over the lease term on a collateralized basis. Periods covered by the Company’s option to extend or terminate the lease are included in the lease term when it is reasonably certain that the Company will exercise its option to extend or not exercise its option to terminate, as applicable. Lease payments may be fixed or variable; however, only fixed payments or in-substance fixed payments are included in the Company’s lease liability calculation. Variable lease payments may include costs such as common area maintenance, utilities, real estate taxes or other costs. Variable lease payments are recognized in operating expenses in the period in which the obligations for those payments are incurred. The Company records rent expense for its operating lease, which has escalating rent payments, on a straight-line basis over the lease term. The Company does not have any financing leases. The Company made a policy election not to separate non-lease components from lease components for all its leases; therefore, it accounts for lease and non-lease components as a single lease component. The Company also elected the short-term lease recognition exemption for all leases that qualify, such that leases with a term of 12 months or less are not recognized on the balance sheet. During the fiscal year ended October 31, 2025, the Company determined that it would no longer be using the leased office space in its business operations and wrote off the related right-of use assets and liability accounts. Impairment of Long-Lived Assets The Company reviews its long-lived assets, which includes definite-lived intangibles, long-lived fixed assets and lease right-of-use assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Factors that could trigger an impairment review include significant under-performance relative to expected historical or projected future operating results, significant changes in the manner of the Company’s use of the acquired assets or the strategy for the Company’s overall business or significant negative industry or economic trends. If this evaluation indicates that the value of the long-lived asset may be impaired, the Company makes an assessment of the recoverability of the net carrying value of the asset over its remaining useful life. If this assessment indicates that the long-lived asset is not recoverable, based on the estimated undiscounted future cash flows of the technology over the remaining useful life, the Company reduces the net carrying value of the related asset to fair value and may adjust the remaining useful life. An impairment analysis is subjective and assumptions regarding future growth rates and operating expense levels can have a significant impact on the expected future cash flows and impairment analysis. The Company evaluated its intangible assets for impairment and recognized an impairment loss of $9,895,503 for the year ended October 31, 2025. Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company recognizes revenue when a customer obtains control of promised goods, in an amount that reflects the consideration that the Company expects to receive in exchange for the goods. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods it transfers to the customer. Under ASC 606, disaggregated revenue from contracts with customers depicts the nature, amount, timing, and uncertainty of revenue and cash flows affected by economic factors. Royalty Revenue On June 13, 2022, KBI entered into the PMI License Agreement with PMPSA, effective as of May 13, 2022 (the “PMI Commencement Date”). Pursuant to the PMI License Agreement, KBI granted PMPSA an exclusive irrevocable license to use its technology, documentation, and intellectual property to make, distribute, and sell disposable nicotine e-cigarettes Products based on the intellectual property in certain international markets set forth in the PMI License Agreement (the “PMI Markets”). The Company has the exclusive international distribution rights to the Products and, in order to allow KBI to fulfill its obligations set forth in the PMI License Agreement, has contributed the international distribution rights for the PMI Markets to KBI as set forth in a Capital Contribution Agreement, dated June 10, 2022. The sublicense granted to PMPSA is exclusive in the PMI Markets and neither KBI nor any of its affiliates can sell, promote, use, or distribute any competing products in the PMI Markets for the duration of the term of the PMI License Agreement and any Sell-Out Period (as defined in the PMI License Agreement). PMSPA will be responsible for any regulatory filings necessary to sell the Products in the PMI Markets. Both KBI and PMPSA agree to work together in the registration and maintenance of the Intellectual Property, but KBI will bear all cost and expense to implement the registration strategy. Finally, PMPSA has agreed to potential future development services with KBI in the PMI Markets and has been granted certain rights with respect to potential future products. The initial term of the PMI License Agreement is five (5) years and automatically renews for an additional five-year period unless PMPSA has failed to meet the agreed upon minimum key performance indicators set forth in the PMI License Agreement, in which case the PMI License Agreement will automatically terminate at the end of the initial license term. In consideration for the grant of the licensed rights, PMPSA agreed to pay to KBI a royalty equal to a percentage of the base price of the first sale of each unit of Product manufactured. In addition, before the launch of the first product in a market and each anniversary of such launch, PMPSA agrees to pre-pay to KBI a guaranteed minimum royalty based on the estimated royalties payable by PMPSA to KBI in relation to all markets in the twelve (12)-month period following the first launch or each successive anniversary of the first launch, subject to an aggregate maximum guaranteed royalty payment for all markets for each applicable twelve (12)-month period. PMPSA may require modification of certain products to be sold under the PMI Licensing Agreement to be modified for a PMI Market. Pursuant to the PMI Licensing Agreement, PMPSA has absolute discretion over sales, marketing, product branding and packaging pertaining to sales in the PMI Markets, as well as the right to select the specific PMI Markets in which to launch commercialization and determine what product types are to be promoted in each market, subject to sales and marketing plans and annual business plans set by PMPSA and certain expansion criteria agreed between PMPSA and KBI. Royalty revenue earned from the PMI License Agreement is recognized in the period the sales of the Product manufactured occurs. The PMI License Agreement contains customary representations, warranties, covenants, and indemnification provisions; however, KBI’s liability under the PMI License Agreement is capped at the greater of: (i) Ten Million Dollars ($10,000,000); or (ii) an amount equal to the total of the royalties due to KBI (but not yet paid) plus the royalties (including the guaranteed royalty payment) paid to KBI pursuant to the PMI License Agreement during the immediately preceding twelve (12) consecutive months, provided that such amount shall not exceed Thirty Million Dollars ($30,000,000). On June 10, 2022, Bidi entered into a License Agreement (the “KBI License Agreement”) with KBI, pursuant to which KBI has the exclusive irrevocable license to use Bidi’s licensed intellectual property to the extent necessary for KBI to fulfill its obligations set forth in the PMI Licensing Agreement. Such irrevocable license includes: (i) the right of KBI to grant sub-licenses to PMPSA under the PMI License Agreement for the express purposes set forth in the PMI License Agreement, but for no other purpose; (ii) the right of KBI to grant to PMPSA the right to grant sub-sub-licenses in the manner set forth in the PMI License Agreement, but for no other purpose; and (iii) certain branding rights to the extent (but only to the extent) necessary to permit KBI to perform its obligations to PMPSA as set forth in the PMI License Agreement. On August 12, 2023, the Company executed and entered into a Deed of Amendment No. 1 (the “PMI License Amendment”) with PMPSA, Bidi and KBI. Pursuant to the PMI License Amendment (which has an effective date of June 30, 2023), the following material changes have been made to the PMI License Agreement: 1. Royalty Rate. The royalty paid by PMPSA to KBI will no longer be based on sales price of the Product being sold, but rather on the volume of liquid contained within Product being sold. The royalty will be on a sliding scale of between $0.08 to $0.16 per sale based on the volume of liquid contained in the Product, increasing to between $0.10 to $0.20 per sale upon meeting certain sales milestones. For purposes of determining aggregate sales threshold, all sales undertaken since commencement of the PMI Licensing Agreement will be counted. 2. Elimination of Certain Potential Royalty Adjustments. Certain potential adjustments to the royalties receivable by KBI as provided for in the PMI License Agreement have been eliminated. 3. Guaranteed Royalty. The guaranteed royalty payment owed to KBI under the PMI License Agreement has been eliminated. Instead, royalties will be paid on a quarterly basis going-forward based on actual sales. Any unpaid guaranteed royalty has been cancelled. 4. Insurance Tail Requirements. KBI’s requirement to keep certain tail insurance after the expiration or termination of the PMI Licensing Agreement was reduced from 6 years to 2 years. 5. Markets. The identification of the PMI Markets that PMI may enter has been expanded to cover certain additional territories. 6. Net Reconciliation Payment to KBI. As a result of the changes to the PMI License Agreement described in paragraphs 1 thought 3 above, the value of such changes was calculated and reconciled as of the date of commencement of the PMI Licensing Agreement through June 30, 2023. The KBI License Agreement provides that KBI shall pay Bidi license fees equivalent to 50% of the adjusted earned royalty payments, after any offsets due to jointly agreed costs such development costs incurred for entry to specific international markets. During the three and six months ended April 30, 2026, the Company paid license fees of $32,500 and $70,000, respectively to Bidi. As of April 30, 2026 and October 31, 2025, $30,000 and $50,000, respectively, of license fees are owed to Bidi. As of April 30, 2026 and 2025, amounts receivable from PMPSA in connection with the PMI License Agreement totaled $80,000 and $70,000, respectively. Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potential common stock equivalents. Diluted net loss per share is calculated by dividing net loss available to common stockholders by the weighted average number of common stock outstanding plus common share equivalents from conversion of dilutive stock options and warrants using the treasury method and preferred stock using the if-converted method, except when antidilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive. Share-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments (share-based payments, referred to herein as “SBP”) based on the grant-date fair value of the award. That cost is recognized over the period during which a recipient is required to provide service in exchange for the SBP award—the requisite service period (vesting period). For SBP awards subject to performance conditions, compensation is not recognized until the performance condition is probable of occurrence. The grant-date fair value of share options is estimated using the Black-Scholes-Merton option-pricing model. The fair value of each option granted during the fiscal six month period ended April 30, 2026, was estimated on the date of grant using the Black-Scholes-Merton option-pricing model with the weighted average assumptions in the following table: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSSDowBmJCJe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basis of Presentation and Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of weighted average assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">As of April</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">30, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Expected dividend yield</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251101__20260430_zyFnJh3WI777" style="width: 18%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected option term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430_zN3pbDsDPfT6" title="Expected option term (years)">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260430__srt--RangeAxis__srt--MinimumMember_zhEoWYyA8HPa" title="Expected volatility">250% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260430__srt--RangeAxis__srt--MaximumMember_zM6jaznemMP7" title="Expected volatility">257</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.92</td><td style="text-align: left">%</td></tr> </table> The expected term of options granted represents the period of time that options granted are expected to be outstanding. The expected volatility was based on the volatility in the trading of the Company’s common stock. The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant’s expected term. Forfeitures and cancellations are recorded as they occur. Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; padding-right: 0.8pt; text-align: justify">●</td> <td style="width: 99%; padding-right: 0.8pt; text-align: justify">Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; padding-right: 0.8pt; text-align: justify">●</td> <td style="width: 99%; padding-right: 0.8pt; text-align: justify">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; padding-right: 0.8pt; text-align: justify">●</td> <td style="width: 99%; padding-right: 0.8pt; text-align: justify">Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</td></tr> </table> Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of April 30, 2026 and October 31, 2025. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable, accrued expenses and loans payable. As of April 30, 2026 and October 31, 2025, the Company did not have any financial assets or liabilities measured and recorded at fair value on a recurring basis. Recent Accounting Pronouncements – Not Yet Adopted In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which simplifies the application of the current expected credit loss model for current receivables and current contract assets under Accounting Standards Codification 606. The update will be effective for annual reporting periods beginning after December 15, 2025, and interim periods within those annual reporting periods. Early adoption is permitted. We are assessing the effects of this update on our consolidated financial statements and related disclosures. In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires additional disclosures reconciling the rates of different categories of income tax (i.e. federal, state, foreign, etc.) and a disaggregation of taxes paid and refunded. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and for interim periods in fiscal years beginning after December 15, 2025, although early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its income tax disclosures.

Principles of Consolidation The consolidated financial statements include the financial statements of the Company’s wholly-owned subsidiaries, Kaival Labs and Kaival Brands International. Intercompany transactions are eliminated.

Basis of Presentation The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent audited financial statements contained within the Company’s Annual Report on Form 10-K, filed with the SEC on January 29, 2026 (the “2025 Annual Report”). In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full fiscal year. Notes to the consolidated financial statements, which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period as reported in the 2025 Annual Report, have been omitted.

Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

Cash The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of April 30, 2026, and October 31, 2025. The Federal Deposit Insurance Corporation (“FDIC”) insures deposits according to the ownership category in which the funds are insured and how the accounts are titled. The standard deposit insurance coverage limit is $250,000 per depositor, per FDIC-insured bank, per ownership category. The Company had uninsured cash of $27,951 and $284,406 as of April 30, 2026, and October 31, 2025, respectively.

250000

27951

284406

Advertising and Promotion All advertising, promotion and marketing expenses, including commissions, are expensed when incurred.

Accounts Receivable and Reserve for Credit Loss Accounts receivable pertain to contracts with customers who are granted credit by the Company in the ordinary course of business and are recorded at the invoiced amount. Accounts receivable does not bear interest. Accounts receivable presented on the consolidated balance sheet are adjusted for any write-offs and net of allowance for credit losses. The Company’s reserve for credit losses is developed by using relevant available information including historical collection and loss experience, current economic conditions, prevailing economic conditions, supportable forecasted economic conditions and evaluations of customer balances. Once a receivable is deemed uncollectible after collection efforts have been exhausted, it is written off against the reserve for credit losses. The Company closely monitors the credit quality of its customers and does not generally require collateral or other security on receivables. The reserve for credit losses is measured on a collective basis when similar risk characteristics exist. Based upon management’s assessment of the accounts receivable aging and the customers’ payment history, the Company has determined that no reserve for credit losses is required as of April 30, 2026 and October 31, 2025.

Credit Risk Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of purchases of inventories, accounts payable, accounts receivable, and revenue. The Company performs periodic credit evaluations of its customers and generally does not require collateral on trade receivables. Historically, the Company has not experienced significant credit losses.

Leases The Company determines if a contract contains a lease at commencement of the arrangement based on whether it has the right to obtain substantially all of the economic benefits from the use of an identified asset and whether it has the right to direct the use of an identified asset in exchange for consideration, which relates to an asset which the Company does not own. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company recognizes lease liabilities at the present value of the future lease payments and a corresponding ROU asset at the lease commencement date. The interest rate used to determine the present value of the future lease payments is the rate implicit in the lease unless that rate cannot be readily determined. When the interest rate implicit in the lease is not readily determinable, the interest rate used to determine the present value of the future lease payments is the Company’s Incremental Borrowing Rate (“IBR”). The IBR is a hypothetical rate based on the Company’s understanding of what its credit rating would be to borrow and resulting interest the Company would pay to borrow an amount equal to the lease payments in a similar economic environment over the lease term on a collateralized basis. Periods covered by the Company’s option to extend or terminate the lease are included in the lease term when it is reasonably certain that the Company will exercise its option to extend or not exercise its option to terminate, as applicable. Lease payments may be fixed or variable; however, only fixed payments or in-substance fixed payments are included in the Company’s lease liability calculation. Variable lease payments may include costs such as common area maintenance, utilities, real estate taxes or other costs. Variable lease payments are recognized in operating expenses in the period in which the obligations for those payments are incurred. The Company records rent expense for its operating lease, which has escalating rent payments, on a straight-line basis over the lease term. The Company does not have any financing leases. The Company made a policy election not to separate non-lease components from lease components for all its leases; therefore, it accounts for lease and non-lease components as a single lease component. The Company also elected the short-term lease recognition exemption for all leases that qualify, such that leases with a term of 12 months or less are not recognized on the balance sheet. During the fiscal year ended October 31, 2025, the Company determined that it would no longer be using the leased office space in its business operations and wrote off the related right-of use assets and liability accounts.

Impairment of Long-Lived Assets The Company reviews its long-lived assets, which includes definite-lived intangibles, long-lived fixed assets and lease right-of-use assets, for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Factors that could trigger an impairment review include significant under-performance relative to expected historical or projected future operating results, significant changes in the manner of the Company’s use of the acquired assets or the strategy for the Company’s overall business or significant negative industry or economic trends. If this evaluation indicates that the value of the long-lived asset may be impaired, the Company makes an assessment of the recoverability of the net carrying value of the asset over its remaining useful life. If this assessment indicates that the long-lived asset is not recoverable, based on the estimated undiscounted future cash flows of the technology over the remaining useful life, the Company reduces the net carrying value of the related asset to fair value and may adjust the remaining useful life. An impairment analysis is subjective and assumptions regarding future growth rates and operating expense levels can have a significant impact on the expected future cash flows and impairment analysis. The Company evaluated its intangible assets for impairment and recognized an impairment loss of $9,895,503 for the year ended October 31, 2025.

9895503

Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The Company recognizes revenue when a customer obtains control of promised goods, in an amount that reflects the consideration that the Company expects to receive in exchange for the goods. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods it transfers to the customer. Under ASC 606, disaggregated revenue from contracts with customers depicts the nature, amount, timing, and uncertainty of revenue and cash flows affected by economic factors.

Royalty Revenue On June 13, 2022, KBI entered into the PMI License Agreement with PMPSA, effective as of May 13, 2022 (the “PMI Commencement Date”). Pursuant to the PMI License Agreement, KBI granted PMPSA an exclusive irrevocable license to use its technology, documentation, and intellectual property to make, distribute, and sell disposable nicotine e-cigarettes Products based on the intellectual property in certain international markets set forth in the PMI License Agreement (the “PMI Markets”). The Company has the exclusive international distribution rights to the Products and, in order to allow KBI to fulfill its obligations set forth in the PMI License Agreement, has contributed the international distribution rights for the PMI Markets to KBI as set forth in a Capital Contribution Agreement, dated June 10, 2022. The sublicense granted to PMPSA is exclusive in the PMI Markets and neither KBI nor any of its affiliates can sell, promote, use, or distribute any competing products in the PMI Markets for the duration of the term of the PMI License Agreement and any Sell-Out Period (as defined in the PMI License Agreement). PMSPA will be responsible for any regulatory filings necessary to sell the Products in the PMI Markets. Both KBI and PMPSA agree to work together in the registration and maintenance of the Intellectual Property, but KBI will bear all cost and expense to implement the registration strategy. Finally, PMPSA has agreed to potential future development services with KBI in the PMI Markets and has been granted certain rights with respect to potential future products. The initial term of the PMI License Agreement is five (5) years and automatically renews for an additional five-year period unless PMPSA has failed to meet the agreed upon minimum key performance indicators set forth in the PMI License Agreement, in which case the PMI License Agreement will automatically terminate at the end of the initial license term. In consideration for the grant of the licensed rights, PMPSA agreed to pay to KBI a royalty equal to a percentage of the base price of the first sale of each unit of Product manufactured. In addition, before the launch of the first product in a market and each anniversary of such launch, PMPSA agrees to pre-pay to KBI a guaranteed minimum royalty based on the estimated royalties payable by PMPSA to KBI in relation to all markets in the twelve (12)-month period following the first launch or each successive anniversary of the first launch, subject to an aggregate maximum guaranteed royalty payment for all markets for each applicable twelve (12)-month period. PMPSA may require modification of certain products to be sold under the PMI Licensing Agreement to be modified for a PMI Market. Pursuant to the PMI Licensing Agreement, PMPSA has absolute discretion over sales, marketing, product branding and packaging pertaining to sales in the PMI Markets, as well as the right to select the specific PMI Markets in which to launch commercialization and determine what product types are to be promoted in each market, subject to sales and marketing plans and annual business plans set by PMPSA and certain expansion criteria agreed between PMPSA and KBI. Royalty revenue earned from the PMI License Agreement is recognized in the period the sales of the Product manufactured occurs. The PMI License Agreement contains customary representations, warranties, covenants, and indemnification provisions; however, KBI’s liability under the PMI License Agreement is capped at the greater of: (i) Ten Million Dollars ($10,000,000); or (ii) an amount equal to the total of the royalties due to KBI (but not yet paid) plus the royalties (including the guaranteed royalty payment) paid to KBI pursuant to the PMI License Agreement during the immediately preceding twelve (12) consecutive months, provided that such amount shall not exceed Thirty Million Dollars ($30,000,000). On June 10, 2022, Bidi entered into a License Agreement (the “KBI License Agreement”) with KBI, pursuant to which KBI has the exclusive irrevocable license to use Bidi’s licensed intellectual property to the extent necessary for KBI to fulfill its obligations set forth in the PMI Licensing Agreement. Such irrevocable license includes: (i) the right of KBI to grant sub-licenses to PMPSA under the PMI License Agreement for the express purposes set forth in the PMI License Agreement, but for no other purpose; (ii) the right of KBI to grant to PMPSA the right to grant sub-sub-licenses in the manner set forth in the PMI License Agreement, but for no other purpose; and (iii) certain branding rights to the extent (but only to the extent) necessary to permit KBI to perform its obligations to PMPSA as set forth in the PMI License Agreement. On August 12, 2023, the Company executed and entered into a Deed of Amendment No. 1 (the “PMI License Amendment”) with PMPSA, Bidi and KBI. Pursuant to the PMI License Amendment (which has an effective date of June 30, 2023), the following material changes have been made to the PMI License Agreement: 1. Royalty Rate. The royalty paid by PMPSA to KBI will no longer be based on sales price of the Product being sold, but rather on the volume of liquid contained within Product being sold. The royalty will be on a sliding scale of between $0.08 to $0.16 per sale based on the volume of liquid contained in the Product, increasing to between $0.10 to $0.20 per sale upon meeting certain sales milestones. For purposes of determining aggregate sales threshold, all sales undertaken since commencement of the PMI Licensing Agreement will be counted. 2. Elimination of Certain Potential Royalty Adjustments. Certain potential adjustments to the royalties receivable by KBI as provided for in the PMI License Agreement have been eliminated. 3. Guaranteed Royalty. The guaranteed royalty payment owed to KBI under the PMI License Agreement has been eliminated. Instead, royalties will be paid on a quarterly basis going-forward based on actual sales. Any unpaid guaranteed royalty has been cancelled. 4. Insurance Tail Requirements. KBI’s requirement to keep certain tail insurance after the expiration or termination of the PMI Licensing Agreement was reduced from 6 years to 2 years. 5. Markets. The identification of the PMI Markets that PMI may enter has been expanded to cover certain additional territories. 6. Net Reconciliation Payment to KBI. As a result of the changes to the PMI License Agreement described in paragraphs 1 thought 3 above, the value of such changes was calculated and reconciled as of the date of commencement of the PMI Licensing Agreement through June 30, 2023. The KBI License Agreement provides that KBI shall pay Bidi license fees equivalent to 50% of the adjusted earned royalty payments, after any offsets due to jointly agreed costs such development costs incurred for entry to specific international markets. During the three and six months ended April 30, 2026, the Company paid license fees of $32,500 and $70,000, respectively to Bidi. As of April 30, 2026 and October 31, 2025, $30,000 and $50,000, respectively, of license fees are owed to Bidi. As of April 30, 2026 and 2025, amounts receivable from PMPSA in connection with the PMI License Agreement totaled $80,000 and $70,000, respectively. Royalty Rate. The royalty paid by PMPSA to KBI will no longer be based on sales price of the Product being sold, but rather on the volume of liquid contained within Product being sold. The royalty will be on a sliding scale of between $0.08 to $0.16 per sale based on the volume of liquid contained in the Product, increasing to between $0.10 to $0.20 per sale upon meeting certain sales milestones.

32500

70000

30000

50000

80000

70000

Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potential common stock equivalents. Diluted net loss per share is calculated by dividing net loss available to common stockholders by the weighted average number of common stock outstanding plus common share equivalents from conversion of dilutive stock options and warrants using the treasury method and preferred stock using the if-converted method, except when antidilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive.

Share-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments (share-based payments, referred to herein as “SBP”) based on the grant-date fair value of the award. That cost is recognized over the period during which a recipient is required to provide service in exchange for the SBP award—the requisite service period (vesting period). For SBP awards subject to performance conditions, compensation is not recognized until the performance condition is probable of occurrence. The grant-date fair value of share options is estimated using the Black-Scholes-Merton option-pricing model. The fair value of each option granted during the fiscal six month period ended April 30, 2026, was estimated on the date of grant using the Black-Scholes-Merton option-pricing model with the weighted average assumptions in the following table: <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSSDowBmJCJe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basis of Presentation and Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of weighted average assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">As of April</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">30, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Expected dividend yield</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251101__20260430_zyFnJh3WI777" style="width: 18%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected option term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430_zN3pbDsDPfT6" title="Expected option term (years)">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260430__srt--RangeAxis__srt--MinimumMember_zhEoWYyA8HPa" title="Expected volatility">250% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260430__srt--RangeAxis__srt--MaximumMember_zM6jaznemMP7" title="Expected volatility">257</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.92</td><td style="text-align: left">%</td></tr> </table> The expected term of options granted represents the period of time that options granted are expected to be outstanding. The expected volatility was based on the volatility in the trading of the Company’s common stock. The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant’s expected term. Forfeitures and cancellations are recorded as they occur.

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSSDowBmJCJe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basis of Presentation and Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Schedule of weighted average assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">As of April</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">30, 2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Expected dividend yield</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20251101__20260430_zyFnJh3WI777" style="width: 18%; text-align: right" title="Expected dividend yield">0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected option term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430_zN3pbDsDPfT6" title="Expected option term (years)">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260430__srt--RangeAxis__srt--MinimumMember_zhEoWYyA8HPa" title="Expected volatility">250% - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251101__20260430__srt--RangeAxis__srt--MaximumMember_zM6jaznemMP7" title="Expected volatility">257</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.92</td><td style="text-align: left">%</td></tr> </table>

P5Y

2.50

2.57

0.0392

Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; padding-right: 0.8pt; text-align: justify">●</td> <td style="width: 99%; padding-right: 0.8pt; text-align: justify">Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; padding-right: 0.8pt; text-align: justify">●</td> <td style="width: 99%; padding-right: 0.8pt; text-align: justify">Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 1%; padding-right: 0.8pt; text-align: justify">●</td> <td style="width: 99%; padding-right: 0.8pt; text-align: justify">Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</td></tr> </table> Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of April 30, 2026 and October 31, 2025. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable, accrued expenses and loans payable. As of April 30, 2026 and October 31, 2025, the Company did not have any financial assets or liabilities measured and recorded at fair value on a recurring basis.

Recent Accounting Pronouncements – Not Yet Adopted In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which simplifies the application of the current expected credit loss model for current receivables and current contract assets under Accounting Standards Codification 606. The update will be effective for annual reporting periods beginning after December 15, 2025, and interim periods within those annual reporting periods. Early adoption is permitted. We are assessing the effects of this update on our consolidated financial statements and related disclosures. In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740) - Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 requires additional disclosures reconciling the rates of different categories of income tax (i.e. federal, state, foreign, etc.) and a disaggregation of taxes paid and refunded. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and for interim periods in fiscal years beginning after December 15, 2025, although early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its income tax disclosures.

Note 3 – Going Concern Our accompanying consolidated financial statements are prepared in accordance with U.S. GAAP applicable to a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial Accounting Standards Board (or FASB), ASC 205 , Presentation of Financial Statements – Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying financial statements are issued. As shown in the accompanying consolidated financial statements, we have incurred recurring losses and negative cash flows from operations for the six months ended April 30, 2026. We will need significant additional funds to satisfy our outstanding payables, fund our working capital, and fully implement our business plan. In addition, our ability to continue as a going concern is adversely affected by the FDA’s denial of Bidi’s PMTA process for its non-tobacco flavored Bidi® Stick as well as our ability to continue to sell the Bidi Stick given the patent infringements claim filed by RJ Reynolds. Likewise, in April 2025, the 11th Circuit upheld FDA’s MDO for the Classic BIDI® Stick. Finally, on November 4, 2025, FDA issued a MDO for the PMTA for the non-tobacco flavored Bidi Sticks. All of these factors raise substantial doubt regarding our ability to continue as a going concern. There can be no assurance that we will be able to obtain additional capital or generate revenues sufficient to sustain operations. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of these or other risks or uncertainties.

Note 4 – Leases During fiscal year 2025, the Company had an operating lease for office and inventory storage space with Just Pick, LLC. Cash flow information related to the above-mentioned lease was as follows: <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_z7UMySxHjWoe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"> Schedule of cash flow information related to leases </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Other Lease Information</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating cash flows from operating leases</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ProceedsFromLeasePayments_pp0p0_c20251101__20260430_zOPBWJxhjgkc" style="text-align: right" title="Operating cash flows from operating leases">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ProceedsFromLeasePayments_pp0p0_c20241101__20250430_zyc2opzETum5" style="text-align: right" title="Operating cash flows from operating leases">(98,756</td><td style="text-align: left">)</td></tr> </table> On April 23, 2025, the Company received a letter of demand from Just Pick, LLC, noting that the Company was in breach of the lease as base rent and operating expenses have not been paid since January 8, 2025. On April 30, 2025, the Company responded and provided Just Pick, LLC with a termination notice. As of April 30, 2025, the Company determined that it would no longer be using the leased office space in its business and recorded a loss on the ROU assets of $707,626, accordingly. In May 2025, the Company paid the total unpaid lease payments through May 2025 amounting to $78,217. On January 7, 2026, the Company executed a settlement agreement with Just Pick, LLC. where both parties agreed to no further payments remaining for the office lease liability. The lease liability was written off as of October 31, 2025 and the Company recognized a net gain of approximately $59,000 from the termination of the lease.

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_z7UMySxHjWoe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"> Schedule of cash flow information related to leases </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2026</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Other Lease Information</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating cash flows from operating leases</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ProceedsFromLeasePayments_pp0p0_c20251101__20260430_zOPBWJxhjgkc" style="text-align: right" title="Operating cash flows from operating leases">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ProceedsFromLeasePayments_pp0p0_c20241101__20250430_zyc2opzETum5" style="text-align: right" title="Operating cash flows from operating leases">(98,756</td><td style="text-align: left">)</td></tr> </table>

-98756

707626

78217

59000

Note 5 – Notes Receivable On March 17, 2026, the Company issued a $50,000 convertible note with an OTC company with a repayment amount of $55,000 (annual interest of 10%) on the date of maturity of March 11, 2027. Upon an event of default the Company may elect to convert the note at a fixed conversion price into common stock of the OTC company. On April 9, 2026, the Company issued a $50,000 note with an OTC company with a repayment amount of $55,000 on the date of maturity of July 8, 2026. The terms of the note required the OTC company to issue to us an equity kicker of 500,000 restricted shares of its common stock with piggyback registration rights. The 500,000 shares were issued to us on June 9, 2026. Based on management’s assessment of credit risk on the notes receivables with the maturity date of March 11, 2027, the Company recognized a credit risk reserve of $50,000 as of April 30, 2026. The Company’s CEO Eric Mosser also serves as a consultant as the Chief Corporate Development Officer on the OTC company.

50000

55000

50000

55000

500000 50000

Note 6 – Stockholders’ Equity Series B Convertible Preferred Stock On May 30, 2023, the Company issued 900,000 shares of the Series B Preferred Stock as consideration for the GoFire asset purchase. The Series B Preferred Stock carries no voting rights except: (i) with respect to the ability of the holders of a majority of the then outstanding Series B Preferred Stock (the “Majority Holders”), to nominate a director to the Company’s board of directors, and (ii) that the vote of the Majority Holders is necessary for effecting any amendment to the Company’s Certificate of Incorporation or Certificate of Designation that affects the Series B Preferred Stock. The Series B Preferred Stock is redeemable at the option of the Company at a redemption price of $<span id="xdx_90C_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20260430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWRgINRiVJB1" title="Preferred stock redemption price per share">15 per share, subject to potential downward adjustments based on the trading price of the Common Stock. Subject to additional limitations in the GoFire APA, the Series B Preferred Stock holds seniority over the Common Stock and each other class of series of securities now existing or hereafter authorized with respect to dividend rights, the distribution of assets upon liquidation, and dissolution and redemption rights. Upon a liquidation and winding up of the Company, the holders of Series B Preferred Stock are entitled to a liquidation preference of $15 per share (the “Liquidation Preference”), though the redemption may be adjusted downward based on the trading price of the Common Stock at the time of liquidation. The holders of Series B Preferred Stock are entitled to receive a dividend equal to 2% of the Liquidation Preference, accruing from the Closing Date and payable on the eighteen-month anniversary of the Closing Date. Amounts payable in respect of the Series B Dividend shall begin to accrue on a daily basis, be cumulative from and including the Original Issue Date, whether or not the Corporation has funds legally available for such dividends or such dividends are declared, shall compound on each six month anniversary of the Original Issue Date and shall be payable in arrears on the 18-month anniversary of the Original Issue Date. No preemptive rights are granted to the holders of Series B Preferred Stock. The Majority Holders have the ability to cause a voluntary conversion of the Series B Preferred Stock into Common Stock at a conversion rate of 0.3968 shares of Common Stock per share of Series B Preferred Stock which may only occur on or after the following dates 18-month, 24 month, 36 month, 48 month, and 60 month anniversary of the original issuance date; and only up to 180,000 shares of Series B Preferred Stock on each of these dates. All shares of Series B Preferred Stock will automatically convert to Common Stock upon the occurrence of a Change of Control (as defined in the GoFire APA). On December 3, 2024, the Company paid accrued dividends of $405,000 to Series B shareholders. As of April 30, 2026, the Company had zero accrued dividend payable to Series B shareholders and no further dividends will be accrued or paid. Pursuant to the GoFire APA, the Company is required to use commercially reasonable efforts to register the APA Shares and Warrant Shares with the SEC for distribution to GoFire’s stockholders and/or public resale by such stockholders within 180 days of the Closing Date. In addition, if any Series B Preferred Stock remains outstanding nineteen (19) months after the Closing Date, the Company shall use commercially reasonable efforts to file with the SEC a subsequent registration statement registering the distribution to GoFire’s stockholders and/or public resale Series B Conversion Shares by such stockholders. If such subsequent registration statement is required, the Company will use its commercially reasonable efforts to obtain effectiveness of such subsequent registration statement within nineteen (19) months of the Closing Date, and if the Company does not so register the Series B Conversion Shares within nineteen (19) months of the Closing Date, the Company will issue to GoFire or its designee an additional ten percent (10%) of all of the Series B Conversion Shares underlying the then outstanding shares of Series B Preferred Stock. All of the securities issued as consideration for the Purchased Assets are subject to a lock-up agreement that terminates one hundred eighty (180) days from the Closing Date. As of April 30, 2026, the Company has accrued the additional ten percent (10%) of all of the Series B Conversion Shares of $39,283. Common Stock During the three months ended January 31, 2026, the Company canceled 2,950,000 fully vested shares of common stock previously issued to directors, and officers as a result of the termination of the merger and share exchange agreement with Delta. During the six months ended April 30, 2026, the Company issued 6,000,000 shares of common stock to directors and officers pursuant to grants under the Company’s Amended and Restated 2020 Stock and Incentive Compensation Plan. During the six months ended April 30, 2026, the Company recognized stock compensation cost of 24,320. The restricted shares vest with an initial 1,200,000 shares vesting immediately upon grant and the remaining shares vesting at 400,000 shares per quarter for the next 12 quarters. The fair value of the shares issued was $91,200. As of April 30, 2026, the unrecognized stock-based compensation expense related to these grants amounted to $66,880. During the three and six months ended April 30, 2025, the Company issued zero and 3,025,000 fully vested shares of common stock, respectively, to directors, officers and an employee pursuant to grants under the Company’s Amended and Restated 2020 Stock and Incentive Compensation Plan. During the three and six months ended April 30, 2025, the Company recognized stock compensation cost of zero and $2,873,750, respectively. Stock Options Summary of stock options information is as follows: <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zu3K7d0nnueg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders Equity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Schedule of stock options information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">WA Exercise</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-weight: bold; text-indent: -10pt">Outstanding, October 31, 2025</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlPLT9Ag5YCa" style="width: 10%; text-align: right" title="Aggregate number of shares outstanding, Beginning">55,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--AggregateExercisePriceOutstanding_iS_pp0p0_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zaE3fjPriiMk" style="width: 10%; text-align: right" title="Aggregate exercise price outstanding, Beginning">848,028</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_c20251101__20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmae8ksVWGRe" title="Exercise price range outstanding, Beginning">3.64-<span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_c20251101__20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgLnXXaNbJNc" title="Exercise price range outstanding, Beginning">59.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhWYI3z62Mj" style="width: 10%; text-align: right" title="Weighted average exercise price outstanding, Beginning">15.23</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPXIbCztII5j" style="text-align: right" title="Aggregate number of shares, Granted">7,586,060</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--AggregateExercisePriceGranted_pp0p0_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0itDvbhWO1" style="text-align: right" title="Aggregate exercise price, Granted">115,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeGrantedOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztJ80UMhxX89" title="Exercise price range, Granted">0.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmP8Qp8CmnUd" style="text-align: right" title="Weighted average exercise price, Granted">0.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXDvYkKIAe82" title="Aggregate number of shares, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisedOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKnXnGGV0o9f" title="Exercise price range, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbj9JCG5gme3" title="Weighted average exercise price, Exercised">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Cancelled, forfeited, or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zURdCW2Yhu7d" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate number of shares, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--AggregateExercisePriceCancelledForfeitedOrExpired_pp0p0_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwhbZl57vOqj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate exercise price, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeCancelledForfeitedOrExpiredOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zC4M52F0bdcg" title="Exercise price range, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMoJxt44Vob9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Outstanding, April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmTgTgR0E0xg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate number of shares outstanding, Ending">7,641,727</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--AggregateExercisePriceOutstanding_iE_pp0p0_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLjt7q9HpIuf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate exercise price outstanding, Ending">963,336</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_c20251101__20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9kaMVv7iAB1" title="Exercise price range outstanding, Ending">0.02-<span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_c20251101__20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTIDzuY1caj5" title="Exercise price range outstanding, Ending">59.85</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZqeCI883Xbg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Ending">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Exercisable, April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zStgj5EYwrA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate number of shares, Exercisable">2,322,507</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--AggregateExercisePriceExercisable_iI_pp0p0_c20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXohvX0f81Be" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate exercise price, Exercisable">862,788</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUMNBYK5o8Yb" title="Exercise price range, Exercisable">0.02-<span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxdyyM67AeA1" title="Exercise price range, Exercisable">59.85</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5cD6p3lkdri" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> On March 31, 2026, the Company granted 7,586,060 stock options to directors, officers and an employee. The exercise price of the granted stock options is $0.0152 and the stock options vest over a period of 1 to 3 years. During the three months ended April 30, 2026, and 2025, the Company recognized $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpenses_pp0p0_c20260201__20260430__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zy9P9fbxjCE" title="Stock option expense">32,494 and $<span id="xdx_908_ecustom--StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpenses_pp0p0_c20251101__20260430__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zD54pJDyEXbe" title="Stock option expense">2,445, respectively of stock option expense related to outstanding stock options. The weighted-average grant-date fair value of the options granted during the three months ended April 30, 2026, was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260201__20260430_zbsFVJGyVr2g" title="weighted-average grant-date fair value of the options granted">0.02. As of April 30, 2026, the Company had $92,024 of unrecognized expenses related to options, which is expected to be recognized over a weighted-average period of approximately <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20251101__20260430_z0r6IL5Fla2" title="Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition">2.10 years. The weighted average remaining contractual life is approximately <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20251101__20260430_zuhYYK8haMdc" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term">9.93 years for stock options outstanding as of April 30, 2026. The aggregate intrinsic value of these outstanding options as of April 30, 2026, was $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20260430_zib1U01UTMoj" title="Aggregate intrinsic value">119,860. Warrants Warrant information as of the periods indicated is as follows: <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXx8QG1zJK9k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders Equity (Details1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Schedule of warrant information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Average</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Number</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price Range</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-weight: bold; text-indent: -10pt">Outstanding, October 31, 2025</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZPYVtkc2iyh" style="width: 10%; text-align: right" title="Aggregate number of shares outstanding, Beginning">5,754,686</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--AggregateExercisePriceOutstanding_iS_pp0p0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPreK5XUolpe" style="width: 10%; text-align: right" title="Aggregate exercise price outstanding, Beginning">19,826,116</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20251031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zwgKoWNktDli" title="Exercise price range outstanding, Beginning">1.16-<span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20251031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zMbLO30DhpY4" title="Exercise price range outstanding, Beginning">126.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcY09520Vvia" style="width: 10%; text-align: right" title="Weighted average exercise price outstanding, Beginning">3.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkFFZxdHMwMh" style="text-align: right" title="Aggregate number of shares, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--AggregateExercisePriceGranted_pdp0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8ayUS2Ey1Ck" style="text-align: right" title="Aggregate exercise price, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeGrantedOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1xWUnq2Rgsl" title="Exercise price range, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuXGANRgbe" style="text-align: right" title="Weighted average exercise price, Granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsTCURyXYqm5" style="text-align: right" title="Aggregate number of shares, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--AggregateExercisePriceExercised_pp0p0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z96ZlUbraPRg" style="text-align: right" title="Aggregate exercise price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisedOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAXGoncopzx8" title="Exercise price range, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn475eGI1pFc" style="text-align: right" title="Weighted average exercise price, Exercised">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Cancelled, forfeited, or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGR8RHYju9yc" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate number of shares, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--AggregateExercisePriceCancelledForfeitedOrExpired_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWgL0VIy0eKi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate exercise price, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeCancelledForfeitedOrExpiredOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztnP8WGfU09c" title="Exercise price range, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0go36Jzxd53" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Outstanding, April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDWOTOlJ28Ta" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate number of shares outstanding, Ending">5,754,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--AggregateExercisePriceOutstanding_iE_pp0p0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQZImly8Xll2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate exercise price outstanding, Ending">19,826,116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOYczkwV65l8" title="Exercise price range outstanding, Ending">1.16-<span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znTSsbcqOQq7" title="Exercise price range outstanding, Ending">126.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXLtkumG7B7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Ending">3.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Exercisable, April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber_iI_c20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2yWFUCHC2Ab" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate number of shares, Exercisable">5,754,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--AggregateExercisePriceExercisable_iI_pp0p0_c20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrhxuusQUHh9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate exercise price, Exercisable">19,826,116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNwOLRvovwwc" title="Exercise price range, Exercisable">1.16-<span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkFkK5lYg0l8" title="Exercise price range, Exercisable">126.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcbvpnVjy2Bd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">3.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The weighted average remaining contractual life is approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20251101__20260430__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember_zDR2wNue2vqf" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term">3.07 years for common stock warrants outstanding as of April 30, 2026. As of April 30, 2026, there was <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_do_c20260430__us-gaap--AwardTypeAxis__custom--CommonStockWarrantsMember_zY0qCJwJWvV4" title="Aggregate intrinsic value">no intrinsic value of outstanding stock warrants.

405000

39283

2950000

6000000

24320 1200000 400000 91200 66880

3025000

2873750

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zu3K7d0nnueg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders Equity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Schedule of stock options information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">WA Exercise</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-weight: bold; text-indent: -10pt">Outstanding, October 31, 2025</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlPLT9Ag5YCa" style="width: 10%; text-align: right" title="Aggregate number of shares outstanding, Beginning">55,667</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--AggregateExercisePriceOutstanding_iS_pp0p0_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zaE3fjPriiMk" style="width: 10%; text-align: right" title="Aggregate exercise price outstanding, Beginning">848,028</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_c20251101__20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmae8ksVWGRe" title="Exercise price range outstanding, Beginning">3.64-<span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iS_c20251101__20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgLnXXaNbJNc" title="Exercise price range outstanding, Beginning">59.85</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhWYI3z62Mj" style="width: 10%; text-align: right" title="Weighted average exercise price outstanding, Beginning">15.23</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zPXIbCztII5j" style="text-align: right" title="Aggregate number of shares, Granted">7,586,060</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--AggregateExercisePriceGranted_pp0p0_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0itDvbhWO1" style="text-align: right" title="Aggregate exercise price, Granted">115,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeGrantedOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztJ80UMhxX89" title="Exercise price range, Granted">0.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmP8Qp8CmnUd" style="text-align: right" title="Weighted average exercise price, Granted">0.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXDvYkKIAe82" title="Aggregate number of shares, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisedOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKnXnGGV0o9f" title="Exercise price range, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbj9JCG5gme3" title="Weighted average exercise price, Exercised">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Cancelled, forfeited, or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zURdCW2Yhu7d" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate number of shares, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--AggregateExercisePriceCancelledForfeitedOrExpired_pp0p0_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwhbZl57vOqj" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate exercise price, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeCancelledForfeitedOrExpiredOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zC4M52F0bdcg" title="Exercise price range, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMoJxt44Vob9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Outstanding, April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmTgTgR0E0xg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate number of shares outstanding, Ending">7,641,727</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--AggregateExercisePriceOutstanding_iE_pp0p0_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLjt7q9HpIuf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate exercise price outstanding, Ending">963,336</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_c20251101__20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9kaMVv7iAB1" title="Exercise price range outstanding, Ending">0.02-<span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iE_c20251101__20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTIDzuY1caj5" title="Exercise price range outstanding, Ending">59.85</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZqeCI883Xbg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Ending">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Exercisable, April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zStgj5EYwrA3" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate number of shares, Exercisable">2,322,507</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--AggregateExercisePriceExercisable_iI_pp0p0_c20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zXohvX0f81Be" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate exercise price, Exercisable">862,788</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zUMNBYK5o8Yb" title="Exercise price range, Exercisable">0.02-<span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zxdyyM67AeA1" title="Exercise price range, Exercisable">59.85</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260430__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5cD6p3lkdri" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

55667

848028

3.64

59.85

15.23

7586060

115308 0.02

0.02

7641727

963336

0.02

59.85

0.13

2322507

862788

0.02

59.85

0.36

7586060 32494 2445

0.02

92024

P2Y1M6D

P9Y11M4D

119860

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXx8QG1zJK9k" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders Equity (Details1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Schedule of warrant information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Average</td></tr> <tr style="vertical-align: bottom"> <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Number</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price Range</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-weight: bold; text-indent: -10pt">Outstanding, October 31, 2025</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZPYVtkc2iyh" style="width: 10%; text-align: right" title="Aggregate number of shares outstanding, Beginning">5,754,686</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--AggregateExercisePriceOutstanding_iS_pp0p0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPreK5XUolpe" style="width: 10%; text-align: right" title="Aggregate exercise price outstanding, Beginning">19,826,116</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20251031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zwgKoWNktDli" title="Exercise price range outstanding, Beginning">1.16-<span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20251031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zMbLO30DhpY4" title="Exercise price range outstanding, Beginning">126.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcY09520Vvia" style="width: 10%; text-align: right" title="Weighted average exercise price outstanding, Beginning">3.45</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkFFZxdHMwMh" style="text-align: right" title="Aggregate number of shares, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--AggregateExercisePriceGranted_pdp0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8ayUS2Ey1Ck" style="text-align: right" title="Aggregate exercise price, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeGrantedOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1xWUnq2Rgsl" title="Exercise price range, Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuXGANRgbe" style="text-align: right" title="Weighted average exercise price, Granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsTCURyXYqm5" style="text-align: right" title="Aggregate number of shares, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--AggregateExercisePriceExercised_pp0p0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z96ZlUbraPRg" style="text-align: right" title="Aggregate exercise price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisedOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAXGoncopzx8" title="Exercise price range, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn475eGI1pFc" style="text-align: right" title="Weighted average exercise price, Exercised">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Cancelled, forfeited, or expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGR8RHYju9yc" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate number of shares, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_ecustom--AggregateExercisePriceCancelledForfeitedOrExpired_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWgL0VIy0eKi" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate exercise price, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeCancelledForfeitedOrExpiredOptionsWeightedAverageExercisePrice_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztnP8WGfU09c" title="Exercise price range, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0go36Jzxd53" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Cancelled forfeited or expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Outstanding, April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDWOTOlJ28Ta" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate number of shares outstanding, Ending">5,754,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--AggregateExercisePriceOutstanding_iE_pp0p0_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQZImly8Xll2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate exercise price outstanding, Ending">19,826,116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOYczkwV65l8" title="Exercise price range outstanding, Ending">1.16-<span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_c20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znTSsbcqOQq7" title="Exercise price range outstanding, Ending">126.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20251101__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXLtkumG7B7i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Ending">3.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding: 0pt 0pt 0pt 20pt; text-indent: -10pt">Exercisable, April 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber_iI_c20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2yWFUCHC2Ab" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate number of shares, Exercisable">5,754,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--AggregateExercisePriceExercisable_iI_pp0p0_c20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrhxuusQUHh9" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate exercise price, Exercisable">19,826,116</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260430__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNwOLRvovwwc" title="Exercise price range, Exercisable">1.16-<span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20260430__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkFkK5lYg0l8" title="Exercise price range, Exercisable">126.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcbvpnVjy2Bd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">3.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5754686

19826116

1.16

126.00

3.45

5754686

19826116

1.16

126.00

3.45

5754686 19826116

1.16

126.00

3.45

P3Y25D

Note 7 – Related-Party Transactions License Fees and Accounts Payable The KBI License agreement provides that KBI shall pay Bidi license fees equivalent to 50% of the adjusted earned royalty payments, after any offsets due to jointly agreed costs such development costs incurred for entry to specific international markets. Bidi is considered a related party because it beneficially owns more than 10% of the Company’s outstanding common stock. During the three and six months ended April 30, 2026, the Company paid license fees of approximately $32,500 and $70,000 , respectively to Bidi. As of April 30, 2026, the Company had a payable to Bidi of $30,000 related to the PMI License Agreement. During the three and six months ended April 30, 2025, the Company paid license fees of approximately $90,000 and $198,215, respectively to Bidi. As of April 30, 2025, the Company had a payable to Bidi of $35,000 related to the PMI License Agreement.

32500

70000

30000

90000

198215

35000

false false false false